OncoMatch/Clinical Trials/NCT06394674
High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib
Is NCT06394674 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Furmonertinib for non-small cell lung cancer.
Treatment: Furmonertinib — This is a prospective, randomised, uncontrolled phase II clinical trial planned to include 84 subjects with metastatic lung adenocarcinoma that had progressed after first- or second-line treatment with Osmertinib, who were randomly assigned to trial group 1 and trial group 2, and were given Furmonertinib 160 mg and 240 mg once/day, orally, respectively, with efficacy evaluated every 6 weeks until disease progression, intolerable toxic side effects, or Subjects voluntarily withdrew informed consent.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR sensitizing mutation
Required: EGFR t790m
Disease stage
Metastatic disease required
metastatic lung adenocarcinoma; at least 1 measurable lesion according to RECIST 1.1
Prior therapy
Must have received: EGFR tyrosine kinase inhibitor (osimertinib) — first- or second-line
Progression of imaging-confirmed extracranial lesions after first- or second-line treatment with Osimertinib
Cannot have received: chemotherapy
Previous chemotherapy
Cannot have received: immunotherapy
Previous immunotherapy
Lab requirements
Blood counts
Normal functioning of major organs
Kidney function
Normal functioning of major organs
Liver function
Normal functioning of major organs
Normal functioning of major organs
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify